Bullous keratopathy sales will strengthen through 2036, anchored by emmecell at 55% of the therapies segment in 2026. The market was valued at USD 465.18 million in 2025 and is expected to be worth USD 708.70 million by 2036, creating an incremental opportunity of USD 315.62 million worldwide.